ADC Therapeutics gets the nod from the FDA for its CD19-targeted antibody drug conjugate

The US Food and Drug Administration (FDA) has approved ADC Therapeutics’ ZYNLONTA as a third-line therapy for patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).